United Therapeutics Stock Price Prediction
| UTHR Stock | USD 237.00 2.53 1.08% |
Oversold Vs Overbought
54
Oversold | Overbought |
United Therapeutics stock price prediction is an act of determining the future value of United Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of United Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of United Therapeutics and does not consider all of the tangible or intangible factors available from United Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with United Therapeutics, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting United Therapeutics' stock price prediction:Quarterly Earnings Growth 0.626 | EPS Estimate Next Quarter 5.3 | EPS Estimate Current Year 24.04 | EPS Estimate Next Year 24.85 | Wall Street Target Price 292.25 |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of United Therapeutics based on different types of headlines from major news networks to social media. The United stock price prediction module provides an analysis of price elasticity to changes in media outlook on United Therapeutics over a specific investment horizon. Using United Therapeutics hype-based prediction, you can estimate the value of United Therapeutics from the perspective of United Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards United Therapeutics using United Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards United using crowd psychology based on the activity and movement of United Therapeutics' stock price.
United Therapeutics Short Interest
A significant increase or decrease in United Therapeutics' short interest from the previous month could be a good indicator of investor sentiment towards United. Short interest can provide insight into the potential direction of United Therapeutics stock and how bullish or bearish investors feel about the market overall. An investor who is long United Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about United Therapeutics and may potentially protect profits, hedge United Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 229.4439 | Short Percent 0.1177 | Short Ratio 8.9 | Shares Short Prior Month 1.9 M | 50 Day MA 231.7506 |
United Therapeutics Hype to Price Pattern
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of United Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about United Therapeutics.
United Therapeutics Implied Volatility | 34.45 |
United Therapeutics' implied volatility exposes the market's sentiment of United Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if United Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that United Therapeutics stock will not fluctuate a lot when United Therapeutics' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in United Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in United Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying United because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
United Therapeutics after-hype prediction price | USD 237.06 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current United contract
Based on the Rule 16, the options market is currently suggesting that United Therapeutics will have an average daily up or down price movement of about 2.15% per day over the life of the 2024-05-17 option contract. With United Therapeutics trading at USD 237.0, that is roughly USD 5.1 . If you think that the market is fully incorporating United Therapeutics' daily price movement you should consider acquiring United Therapeutics options at the current volatility level of 34.45%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
United |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of United Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
United Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of United Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in United Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of United Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
United Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting United Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on United Therapeutics' historical news coverage. United Therapeutics' after-hype downside and upside margins for the prediction period are 235.50 and 238.62, respectively. We have considered United Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
United Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of United Therapeutics is based on 3 months time horizon.
United Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with United Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.15 | 1.57 | 0.07 | 0.12 | 11 Events / Month | 11 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
237.00 | 237.06 | 0.03 |
|
United Therapeutics Hype Timeline
United Therapeutics is at this time traded for 237.00. The entity has historical hype elasticity of 0.07, and average elasticity to hype of competition of -0.12. United is forecasted to increase in value after the next headline, with the price projected to jump to 237.06 or above. The average volatility of media hype impact on the company the price is over 100%. The price gain on the next news is projected to be 0.03%, whereas the daily expected return is at this time at 0.15%. The volatility of related hype on United Therapeutics is about 191.74%, with the expected price after the next announcement by competition of 236.88. The company reported the previous year's revenue of 2.33 B. Net Income was 984.8 M with profit before overhead, payroll, taxes, and interest of 1.78 B. Given the investment horizon of 90 days the next forecasted press release will be in about 11 days. Check out United Therapeutics Basic Forecasting Models to cross-verify your projections.United Therapeutics Related Hype Analysis
Having access to credible news sources related to United Therapeutics' direct competition is more important than ever and may enhance your ability to predict United Therapeutics' future price movements. Getting to know how United Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how United Therapeutics may potentially react to the hype associated with one of its peers.
United Therapeutics Additional Predictive Modules
Most predictive techniques to examine United price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for United using various technical indicators. When you analyze United charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About United Therapeutics Predictive Indicators
The successful prediction of United Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as United Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of United Therapeutics based on analysis of United Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to United Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to United Therapeutics's related companies. | 2021 | 2023 | 2024 (projected) | Dividend Yield | 0.007453 | 0.009523 | 0.008938 | Price To Sales Ratio | 5.76 | 4.42 | 4.2 |
Story Coverage note for United Therapeutics
The number of cover stories for United Therapeutics depends on current market conditions and United Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that United Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about United Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
United Therapeutics Short Properties
United Therapeutics' future price predictability will typically decrease when United Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of United Therapeutics often depends not only on the future outlook of the potential United Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. United Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 49.7 M | |
| Cash And Short Term Investments | 3 B |
Check out United Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.81 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.